Showing results (221-230 of 306) with videos related to
Sort By:
Pageof 31
Nature Communications|March 13, 2020
Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapyMohamed Mahameed, Shatha Boukeileh, Akram Obiedat, et al.The Journal of Antimicrobial Chemotherapy|August 7, 2023
Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018Bashkim Jaha, Corinne D Schenkel, Lisa Jörimann, et al.Journal of Neuro-Oncology|April 17, 2024
Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokinesDaniela Kocher, Lei Cao, Romain Guiho, et al.Diagnostic Microbiology and Infectious Disease|August 2, 2015
Unbiased metagenomic sequencing complements specific routine diagnostic methods and increases chances to detect rare viral strainsDagmara W Lewandowska, Osvaldo Zagordi, Andrea Zbinden, et al.Nature Communications|April 5, 2020
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activationShaima'a Hamarsheh, Lena Osswald, Benedikt S Saller, et al.International Journal of Cancer|January 18, 2019
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg casesAnna-Lena Volckmar, Jonas Leichsenring, Martina Kirchner, et al.Acta Neuropathologica|March 23, 2011
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytomaHuriye Cin, Claus Meyer, Ricarda Herr, et al.Journal of Virology|November 13, 2009
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-LAnn J Hessell, Eva G Rakasz, David M Tehrani, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2020
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral TreatmentAshima Pyngottu, Alexandra U Scherrer, Roger Kouyos, et al.Cell Reports. Medicine|August 31, 2024
Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccinesMagdalena Schwarzmüller, Cristina Lozano, Merle Schanz, et al.Pageof 31